Perfluorinated Compounds (PFAS) vs Brominated Vegetable Oil: which is worse?

What is Perfluorinated Compounds (PFAS)?

Per- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemicals characterized by extremely strong carbon-fluorine bonds. They are used in food packaging (grease-resistant coatings), non-stick cookware (PTFE/Teflon), food processing equipment, firefighting foam, and many industrial applications. The 'forever chemicals' moniker reflects their extreme environmental persistence.

What is Brominated Vegetable Oil?

Brominated vegetable oil (BVO) is a food additive created by bonding bromine atoms to vegetable oil (typically soybean oil), creating a denser-than-water compound. When added to citrus-flavored beverages, BVO acts as an emulsifier and weighting agent, keeping citrus flavor oils evenly distributed throughout the drink rather than floating to the surface.

Documented risks

Perfluorinated Compounds (PFAS): PFAS are among the most extensively studied and harmful groups of synthetic chemicals in the modern environment. Their unique carbon-fluorine bond stability means they do not break down in the environment or in human body tissues — contributing to bioaccumulation over a lifetime. Health effects documented in human epidemiological studies include: - Cancer: PFOA (perfluorooctanoic acid) and PFOS (perfluorooctanesulfonic acid) have been associated with kidney cancer, testicular cancer, thyroid cancer, bladder cancer, and non-Hodgkin lymphoma in occupationally exposed workers and community members with contaminated drinking water. IARC classified PFOA as Group 1 (human carcinogen) in 2023 and PFOS as Group 2B. - Endocrine disruption: PFAS disrupt thyroid hormone signaling and sex hormone balance. Multiple studies find associations between PFAS exposure and hypothyroidism, early puberty in girls, and reduced sperm quality. - Immune suppression: studies have found that PFAS exposure is associated with reduced vaccine response in children and adults, suggesting PFAS may impair immune function. - Developmental effects: prenatal PFAS exposure has been associated with lower birth weight, developmental delays, and reduced immune response in infants. - Cholesterol: PFAS exposure consistently raises LDL cholesterol levels, increasing cardiovascular disease risk. The 2023 EPA MCLG (maximum contaminant level goal) for PFOA and PFOS is zero — reflecting the agency's conclusion that there is no safe level. The EPA set enforceable MCLs in drinking water in 2024. The DuPont/3M PFOA/PFOS contamination of drinking water in communities near Teflon manufacturing facilities led to a $671 million settlement (DuPont/Chemours, 2017) and $10.3 billion 3M settlement (2023) — among the largest environmental contamination settlements in history.

Brominated Vegetable Oil: BVO's health concerns center on bromine accumulation in body fat and tissues. Bromine is a halogen related to iodine, and it competes with iodine in the body, potentially disrupting thyroid function—a critical concern since iodine is essential for thyroid hormone synthesis. The FDA-NIH collaborative research directly triggering the 2024 ban found adverse cardiac and thyroid effects in animal studies. This FDA-NIH work, published around 2022–2023, showed effects at dose levels closer to realistic human exposure than previous studies, removing the basis for BVO's safety determination under the Federal Food, Drug, and Cosmetic Act's 'reasonable certainty of no harm' standard. Historical case reports of human toxicity from excessive BVO consumption document bromoderma (skin lesions), memory loss, nerve damage, tremors, and fatigue in individuals consuming large volumes of BVO-containing beverages daily. Two well-documented US cases from the 1970s and 1980s involved bromism (bromine toxicity) from chronic overconsumption. Bromine bioaccumulates in fatty tissues. Long-term sub-clinical accumulation was a concern even before the FDA ban, particularly for heavy consumers of citrus sodas. The EU, Japan, and other countries banned BVO decades ago, making the US one of the last major markets to revoke approval. The FDA issued a proposed rule in November 2023 and a final rule on July 3, 2024, effective August 2, 2024, with compliance deadline August 2, 2025, after which BVO-containing products may not be manufactured for US sale.